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Additional Sources
Underlying Patho
The specific Signs and 
symptoms according to 
(“Angioedema - Immunology; 
Allergic Disorders,” n.d.) 
“edema is often asymmetric 
and mildly painful. It often 
involves the face, lips, and/or 
tongue and may also occur on 
the back of hands or feet or on 
the genitals. Edema of the 
upper airways may cause 
respiratory distress and stridor; 
the stridor may be mistaken for 
asthma. The airways may be 
completely obstructed. Edema 
of the intestines may cause 
nausea, vomiting, colicky 
abdominal pain, and/or 
diarrhea.”
The potential of adverse 
effects from ACE-inhibitors 
should be heavily taken into 
consideration when reviewing 
the patient record and when 
prescribing this medication. The 
dangers of not being prepared 
to deal with this potential life 
threating event could result in 
catastrophic consequences for 
the patient. The CRNA or 
Advanced practice nurse must 
be ready to identify the 
different causative factors and 
treat them in accordance with 
the proper treatment protocol. 
While ACE-inhibitors are a 
wonderful and useful drug that 
can treat multiple disease 
processes the risk must always 
way heavy on the minds of 
those treating patients taking 
these class of medications. The 
goal should be not only to 
spread awareness but 
knowledge that expressly deals 
with the identification and 
treatment of angioedema.        
In anesthesia one of the 
specialty areas would be the 
airway and angioedema affects 
the airway even sometimes to 
the point of compromising the 
airway to the point of 
emergency interventions. 
According to (“Angioedema -
Immunology; Allergic 
Disorders,” n.d.) “Angioedema is 
edema of the deep dermis and 
subcutaneous tissue” “due to 
increased vascular permeability 
include the following mast-cell, 
bradykinin and complement 
mediators”.  While Ace-
inhibitors are well known for 
use to combat hypertension 
they are also according to 
(“Angiotensin-converting 
enzyme (ACE) inhibitors,” n.d.) 
used for “Coronary artery 
disease, Heart failure, Diabetes, 
Kidney disease, MI, Scleroderma 
and Migraines”. Which makes 
there treatment field more 
widely used than many truly 
understand. This makes the risk 
of ACE-inhibitor induced 
angioedema even greater with 
such a wide range of patients. 
While many causes of 
angioedema are known 
According to (“ACE inhibitor-
induced angioedema -
UpToDate,” n.d.) “Angiotensin-
converting enzyme (ACE) 
inhibitors are the leading cause 
of drug-induced angioedema in 
the United States because they 
are so widely prescribed”.
The following article describes 
the process of the 
Pathophysiology concept behind 
Ace-inhibitor Angioedema 
(Campo, Fernandez, Canto, & 
Mayorga, 2013) “ACEI-AAG is due 
to excessive accumulation of 
bradykinin. The reason that only 
a small fraction of patients 
treated with ACE inhibitors 
develop ACEI-AAG may relate to 
genetic variations in bradykinin 
metabolism. During treatment 
with ACE inhibitors, various 
alternative enzymatic pathways 
for metabolism of bradykinin 
become critical (e.g. plasma 
aminopeptidase P). Individuals 
with lower activity of these 
alternative clearance pathways 
may be at increased risk of 
bradykinin accumulation and 
ACEI-AAG.” While many may 
wonder what Bradykinins role is 
according to (“Angioedema,” 
n.d.) “Plasma globulins called 
kininogens release bradykinin 
and cause vascular permeability 
and Inhibition of ACE hinders the 
degradation of bradykinin”
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Conclusion
.
The pathophysiologic concepts are significant in many ways such a 
treatment pathway and understanding risks involved. While many 
treatment options are different they all share a common goal which is 
to stop the progression of airway compromise. The key is choosing 
the correct treatment plan in order to stop the process that is 
occurring whether treating for Mast cell reaction, Bradykinin and 
complement, Acute, chronic, hereditary or acquired angioedema. The 
chosen treatment pathway can have great success or end with the 
death of a patient if the wrong treatment guidelines are chosen. 
While this can be exemplified by the example of treating a mast cell 
reaction as a chronic condition which could compromise the patients 
airway resulting in death or a tracheostomy.
Significance of Patho
According to (“Angioedema - Immunology; Allergic Disorders,” 
n.d.) “For bradykinin-mediated angioedema, epinephrine, 
corticosteroids, and antihistamines have not been shown to be 
effective. Angioedema due to ACE inhibitor use usually resolves about 
24 to 48 h after stopping the drug. If symptoms are severe, 
progressing, or refractory, treatments used for hereditary or acquired 
angioedema can be tried. They include fresh frozen plasma, C1 
inhibitor concentrate, and possibly ecallantide (which inhibits plasma 
kallikrein, required for the generation of bradykinin) 
and icatibant (which blocks bradykinin)”. Also according to 
(“Angioedema - Immunology; Allergic Disorders,” n.d.) “Securing an 
airway is the highest priority” obviously when the patient can no 
longer keep their own airway secure.
Treatment 
While a nurse in advanced 
practice in any setting must be 
vigilant of this lurking threat to 
the most important aspect of 
life we call the airway the CRNA 
must be extra vigilant of the 
medications there patient is 
taking whether the ACE-
inhibitor is new or a lifelong 
medication. The advanced 
practice nurse must know not 
only what type of Angioedema 
the patient is suffering from but 
how to properly treat the 
specific aliment the patient is 
experiencing. Also we must be 
able to bring a calm 
compassionate manner to the 
bedside of these patients who 
are fearful, anxious, and fighting 
for their airway in some cases. 
The hard choice must be made 
to take control of the airway if 
needed in some cases whether 
that be intubation or 
tracheostomy placement but 
this is the choice that lies heavy 
upon the advanced practice 
nurse.  
(“Angioedema - Pharmacy 
and Drugs,” n.d.)
(“Learn It,” n.d.)
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